Laura Sepp-Lorenzino
@LauraSepplore
Followers
984
Following
2K
Media
71
Statuses
356
CSO @Intelliatx 🇺🇸🇦🇷 #GeneEditing #CRISPR #WomenInSTEM Opinions/likes/RT mine & not endorsements.
Boston, MA
Joined April 2014
I am honored to join the Board of @ask_bio Inc. during such a pivotal moment as it advances its clinical and pre-clinical programs toward major milestones. Eager to help realize the full potential of these groundbreaking medicines! #CGT #genetherapy #AAV #BOD
We’re proud to welcome Dr. Laura Sepp-Lorenzino to AskBio’s Board of Directors! With 30+ years of leadership in biotech, her insights will be key as we advance our clinical and pre-clinical #GeneTherapy candidates. Learn more: https://t.co/gnSCatDoOr
#AskBio #Leadership
2
1
11
$NTLA announces its 2025 goals to support the company’s mission to transform the lives of patients and bring forth a new era in medicine: https://t.co/iEIsTjLvXK
#CRISPR #GeneEditing
4
3
69
We made the tough call to restructure our business operations, affecting many of our skilled colleagues. I am committed to supporting them through this transition and serving as a personal reference where I can. Your consideration is greatly appreciated. #ONEintellia #talent
$NTLA announces its 2025 goals to support the company’s mission to transform the lives of patients and bring forth a new era in medicine: https://t.co/iEIsTjLvXK
#CRISPR #GeneEditing
0
1
18
Wishing you a year filled with positivity, creativity, and a commitment to making the world a better place. Let's embrace each day with a spirit of discovery and a drive to create beauty around us. Here's to a year of growth, kindness, and meaningful contributions. #NewYear2025
0
0
16
nex z NEJM article:
nejm.org
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly i...
Impressive data update from our nex-z program (aka NTLA-2001 for #ATTR)! Congrats to all! Teamwork makes the dream work. #OneIntellia
0
1
6
Impressive data update from our nex-z program (aka NTLA-2001 for #ATTR)! Congrats to all! Teamwork makes the dream work. #OneIntellia
#ATTR News: $NTLA announces positive new clinical data from the ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) in patients with #ATTR amyloidosis with cardiomyopathy. Full details here: https://t.co/zCvwGbEOIg. Join us at 12 p.m. ET for a webcast discussing the data, as
2
5
44
This encouraging data update brings us one step closer to making CRISPR-based medicines a reality through innovative science. Excited for the future as we continue to move forward! #HAE #CRISPR #OneIntellia
#HAE $NTLA News: Intellia presents positive results from the Phase 2 study of NTLA-2002 for #hereditaryangioedema at the @ACAAI Scientific Meeting in Boston. Details here: https://t.co/Uao5j83Wd6
1
2
24
#HAE $NTLA News: Intellia presents positive results from the Phase 2 study of NTLA-2002 for #hereditaryangioedema at the @ACAAI Scientific Meeting in Boston. Details here: https://t.co/Uao5j83Wd6
3
11
58
Round of applause to the $NTLA team today! Great news from our #AATDProgram Congratulations! #CRISPR #GeneEditing
NEWS: $NTLA receives authorization by the @MHRAgovuk to initiate a Phase 1/2 of NTLA-3001 for the treatment of #alpha1 antitrypsin deficiency-associated lung disease. This is Intellia's first wholly owned in vivo gene insertion program. https://t.co/exgjWzqqhv
#CRISPR #AATD
5
2
34
Thank you @bradloncar for the opportunity to talk about how $NTLA is advancing the field of #geneediting medicines!
Company News: @intelliatx's Chief Scientific Officer elaborates on the news that the company successfully redosed patients with a CRISPR-based and LNP delivered therapy. $NTLA Full video: https://t.co/PbhTAQaTdc
0
1
23
What a great time to be at Intellia! More good news from our NTLA-2002 program for #hereditaryangioedema. Congrats to the team! #CRISPR #OneIntellia
Intellia announces positive long-term data from its ongoing Phase 1 study of NTLA-2002 for #hereditaryangioedema at @EAACI_HQ 2024 Congress. Full details here: https://t.co/HApgVmi8ds
#HAE #CRISPR #geneediting
1
0
22
Heartfelt congratulations to Professor José M. Polo on being elected as Fellow of the Australian Academy of Sciences!!! https://t.co/nW3MyUnAZj Learn more about José's research here: https://t.co/94yFYxmoXU I’m so proud of you!!! #proudaunt
1
0
10
Significant milestone achieved! Our first patient has been dosed in the MAGNITUDE study for #ATTR. Congrats to the team! #CRISPR #GeneEditing
#ATTR News: Intellia doses the first patient in its Phase 3 MAGNITUDE study of NTLA-2001 for the potential treatment of #transthyretinamyloidosis with cardiomyopathy: https://t.co/lyHPaGe0cE
#GeneEditing #CRISPR
3
1
42
Delivery, delivery, delivery! Join us in Siracusa, Italy from April 4-7 to discuss new advances in nucleic acid delivery and how to solve the remaining challenges! Don't miss this opportunity. Abstract deadline is March 15, 2024. Register here: https://t.co/qRw03d7LKU
1
5
26
$NTLA News: This morning, Intellia announced a strategic collaboration with @ReCodeTx to develop novel #geneeditingtherapies for #cysticfibrosis. Full details here: https://t.co/FpBQ9VSdb2
#CRISPR #CF
2
16
62
Huge congratulations to @VertexPharma and @CRISPRTX for making history with the first-ever FDA approval of a #CRISPR therapy!
0
13
78
Congratulations to @VertexPharma and @CRISPRTX on FDA’s approval of @Casgevy (exa-cell), and to all who contributed to this momentous approval!
1
1
31
Heartfelt congratulations to the $VRTX and $CRSP teams!!!
Amazing news for SCD and beta-thal patients in the UK! Congratulations to $VRTX and $CRSP colleagues on a landmark achievement https://t.co/ADxkDaPsVq
0
0
18
Save the Date: In November, Intellia will present updated data from the ongoing Phase 1 study of NTLA-2001 for the potential treatment of #ATTR and hold an investor call to share third quarter 2023 earnings. Full details here: https://t.co/IO4uPEujYB
#CRISPR #GeneEditing
0
3
17